Comprehensive Management of Coagulopathy in ICU Patients
ICU coagulopathy requires a two-tiered diagnostic approach using Sepsis-Induced Coagulopathy (SIC) criteria for early detection (score ≥4) followed by ISTH overt DIC criteria (score ≥5) for advanced disease, with management stratified by bleeding severity and guided by point-of-care testing when available. 1
Diagnostic Framework
Two-Step Sequential Approach
The ISTH recommends identifying coagulopathy early before progression to irreversible DIC:
Step 1: Screen for Sepsis-Induced Coagulopathy (SIC)
- Score ≥4 indicates SIC 1
- Platelet count: <100 × 10⁹/L (2 points); 100-150 × 10⁹/L (1 point)
- PT ratio: >1.4 (2 points); >1.2 to ≤1.4 (1 point)
- SOFA score: ≥2 (2 points); 1 (1 point)
Step 2: Progress to Overt DIC Criteria if SIC Positive
- Score ≥5 indicates overt DIC 1
- Platelet count: <50 × 10⁹/L (2 points); 50-100 × 10⁹/L (1 point)
- FDP/D-dimer: Strong increase (3 points); Moderate increase (2 points)
- PT prolongation: ≥6 seconds (2 points); 3-6 seconds (1 point)
- Fibrinogen: <100 mg/dL (1 point)
Critical Pitfall: Screening only on ICU admission misses evolving coagulopathy. Repeat screening at 48 hours significantly improves mortality prediction and may improve outcomes through earlier intervention. 1
Management by Clinical Phenotype
Massive Bleeding (>10 units RBC/24h or >4 units/1h)
For Trauma Patients:
Use high-ratio transfusion strategy of at least 1:2 FFP:RBC (conditional recommendation). 2 While RCTs showed no definitive mortality benefit at 24 hours (RR 0.75,95% CI 0.52-1.08) or 30 days (RR 0.93,95% CI 0.72-1.2), observational data excluding early deaths demonstrated persistent benefit (RR 0.67,95% CI 0.68-0.93), and high-ratio strategies improve clinical hemostasis. 2
Practical Implementation:
- Initiate 1:1:2 (FFP:Platelets:RBC) or 1:1:1 ratio immediately
- Do not wait for laboratory confirmation in exsanguinating patients
- Transition to goal-directed therapy once point-of-care testing available
For Non-Traumatic Massive Bleeding:
No specific ratio recommendation exists due to very low certainty evidence. 2 Apply individualized goal-directed therapy using:
- Point-of-care viscoelastic testing (ROTEM/TEG) when available
- Target fibrinogen >150-200 mg/dL with fibrinogen concentrate or cryoprecipitate
- Maintain platelets >50 × 10⁹/L (>100 × 10⁹/L for CNS bleeding)
Tranexamic Acid (TXA) Administration
Administer TXA within 90 minutes of injury for trauma patients - this is the critical therapeutic window. 3
Evidence-Based Timing:
- Within 90 minutes: Significant mortality reduction (17% vs 25% placebo; adjusted RR 0.64,95% CI 0.50-0.82) 3
- Beyond 90 minutes: No mortality benefit (adjusted RR 1.04,95% CI 0.74-1.47) 3
Dosing: 1g IV bolus immediately, followed by 1g infusion over 8 hours 3
Critical Pitfall: The traditional 3-hour window from CRASH-2 is too generous. Benefit concentrates in the first 90 minutes, with risk-benefit ratio becoming unfavorable thereafter. 3
Non-Massive Bleeding
Goal-Directed Approach Using Point-of-Care Testing:
When viscoelastic testing available:
- Assess clot formation time/amplitude → guides fibrinogen/platelet therapy
- Evaluate clot firmness → determines need for factor concentrates
- Measure fibrinolysis → identifies need for antifibrinolytic therapy
When POC unavailable, use conventional coagulation tests:
- PT/INR, aPTT, fibrinogen, platelet count
- Blood gas analysis for pH, calcium, temperature
- Repeat every 30-60 minutes during active bleeding
Targeted Factor Replacement:
- Fibrinogen <150 mg/dL: Fibrinogen concentrate (preferred) or cryoprecipitate 4
- INR >1.5 with bleeding: Prothrombin complex concentrate (PCC) for rapid reversal 4
- Platelet dysfunction: Desmopressin 0.3 mcg/kg for uremic or drug-induced platelet dysfunction 5
Sepsis-Associated Coagulopathy Management
Anticoagulant therapy may improve outcomes specifically in patients with documented coagulopathy or DIC - not in all septic patients. 1 This underscores why the SIC/DIC scoring systems are clinically actionable, not merely diagnostic.
Key Principle: Patients with advanced overt DIC may be beyond the therapeutic window for anticoagulation benefit. Early identification using SIC criteria allows intervention before irreversible progression. 1
Balancing Thrombosis vs Bleeding Risk
ICU coagulopathy presents as two dominant phenotypes that may coexist:
Hemorrhagic Phenotype:
- Hypocoagulable state with hyperfibrinolysis
- Requires hemostatic support as outlined above
- Monitor for transition to thrombotic phase
Thrombotic Phenotype:
- Systemic prothrombotic and antifibrinolytic state
- Requires thromboprophylaxis unless contraindicated
- Consider therapeutic anticoagulation in documented thrombosis
Critical Pitfall: These phenotypes can coexist or rapidly transition. Serial reassessment every 24-48 hours is mandatory, not optional. 6, 5
Physiological Optimization
Address the "lethal triad" aggressively:
- Hypothermia: Maintain core temperature >35°C (coagulation enzymes fail below this)
- Acidosis: Target pH >7.2 (severe acidosis impairs factor function by 50%)
- Hypocalcemia: Maintain ionized calcium >1.0 mmol/L (essential cofactor)
These physiological derangements must be corrected simultaneously with hemostatic interventions - addressing coagulopathy alone without correcting these factors results in treatment failure. 7
Monitoring and Reassessment
Establish a major hemorrhage protocol that includes:
- Automatic laboratory triggers (e.g., SIC score ≥4)
- Predefined transfusion ratios for massive bleeding
- Point-of-care testing availability 24/7
- Clear escalation pathways to interventional radiology/surgery
Repeat coagulation assessment:
- Every 30-60 minutes during active massive bleeding
- Every 4-6 hours for non-massive bleeding
- At 48 hours post-ICU admission regardless of bleeding status
The evidence strongly supports that protocol-driven, early recognition and targeted therapy for coagulopathy reduces mortality more effectively than reactive management. 2, 7